News

TOKYO, Japan, and Haifa, Israel, July 30, 2021 - Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., “Minovia”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by...

Thank you for your continued use of our corporate website. Our corporate website and services had been unavailable due to system failure during the following time periods: from 12:30am to 8:10am on Wednesday, July 21, 2021 (Japan Standard Time) from 10:30pm Tuesday, July 20 to 6:10pm on Wednesday, July 21, 2021 (North America Central Standard Time) from 4:30pm on Tuesday, July 20 to 12:10am on...

-Jointly Developed by Astellas and M. Heart- -Implementing MYHOLTER II into M.Heart’s cloud-type Holter ECG Analysis service- TOKYO and Iwate, July 16, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and M. Heart Co., Ltd. (Headquarters: Iwate, President and CEO: Yoshimi Mizunuma, "M. Heart") launched "MYHOLTER II", a software for the holter analyzer...